DE60232577D1 - Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential - Google Patents

Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential

Info

Publication number
DE60232577D1
DE60232577D1 DE60232577T DE60232577T DE60232577D1 DE 60232577 D1 DE60232577 D1 DE 60232577D1 DE 60232577 T DE60232577 T DE 60232577T DE 60232577 T DE60232577 T DE 60232577T DE 60232577 D1 DE60232577 D1 DE 60232577D1
Authority
DE
Germany
Prior art keywords
chimeric proteins
immunogenic potential
oligomeric complexes
improved immunogenic
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232577T
Other languages
English (en)
Inventor
Filette Marina De
Tom Maria Deroo
Walter Fiers
Marleen Maras
Jou Willy Alfons Min
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Application granted granted Critical
Publication of DE60232577D1 publication Critical patent/DE60232577D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60232577T 2001-01-18 2002-01-18 Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential Expired - Lifetime DE60232577D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01200193 2001-01-18
PCT/EP2002/000628 WO2002074795A2 (en) 2001-01-18 2002-01-18 Oligomeric complexes of chimeric proteins with enhanced immunogenic potential

Publications (1)

Publication Number Publication Date
DE60232577D1 true DE60232577D1 (de) 2009-07-23

Family

ID=8179773

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232577T Expired - Lifetime DE60232577D1 (de) 2001-01-18 2002-01-18 Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential

Country Status (9)

Country Link
US (1) US7449188B2 (de)
EP (1) EP1362109B1 (de)
AT (1) ATE433491T1 (de)
AU (1) AU2002252978B9 (de)
CA (1) CA2435000C (de)
DE (1) DE60232577D1 (de)
DK (1) DK1362109T3 (de)
ES (1) ES2327719T3 (de)
WO (1) WO2002074795A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104147597A (zh) 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2659592C (en) 2006-07-14 2016-10-04 Konstantin V. Pugachev Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
US20100239605A1 (en) * 2006-09-29 2010-09-23 Sanofi Pasteur Biologics Co. Recombinant Rhinovirus Vectors
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
EP2610345B1 (de) 2007-11-27 2015-08-19 Medicago Inc. In transgenen Hämagglutinin exprimierenden Pflanzen produzierte rekombinante Influenza-Virus-ähnliche Partikel (VLPS)
JP2011519828A (ja) 2008-04-18 2011-07-14 バクシネート コーポレーション フラジェリンの欠失変異体と使用方法
WO2009133463A1 (en) * 2008-04-30 2009-11-05 University Of Copenhagen Soluble influenza vaccine
EP2294202B1 (de) * 2008-07-08 2015-05-20 Medicago Inc. Lösliche rekombinante influenza-antigene
US10272148B2 (en) 2009-06-24 2019-04-30 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
WO2011014794A1 (en) 2009-07-31 2011-02-03 Paxvax, Inc. Adenoviral-based vectors
PT3354657T (pt) 2009-09-22 2022-05-06 Medicago Inc Método de preparação de proteínas derivadas de plantas
HUE030724T2 (en) * 2010-04-09 2017-06-28 Univ Utrecht Holding Bv Recombinant multimer influenza proteins
BR112013001514A2 (pt) * 2010-07-23 2016-06-07 Erasmus University Rotterdam Medical Ct vacina para influenza
BR112013024157A2 (pt) * 2011-03-22 2016-12-06 Mucosis Bv composições imunogênicas em forma particulada e métodos para produção destas
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
CA2878427A1 (en) 2012-07-26 2014-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP2914283B1 (de) * 2012-11-05 2020-05-20 Georgia State University Research Foundation, Inc. Universeller influenzaimpfstoff auf basis mehrerer heterologer m2e-proteine
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3512874A2 (de) 2017-11-30 2019-07-24 Grifols Diagnostic Solutions Inc. Immunoassays und manipulierte proteine zur überwachung von antikörperbehandlungen gegen die immun-checkpoint-inhibitoren pd-1 und pd-l1
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
EP4022046A2 (de) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenzaviren mit stabilisiertem ha zur replikation in eiern
WO2021150874A1 (en) * 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US20240075152A1 (en) * 2021-01-13 2024-03-07 Purdue Research Foundation Supramolecular assemblies, compositions and methods for producing and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
ES2198414T3 (es) * 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
US5721340A (en) * 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
WO1999062953A1 (en) * 1998-06-04 1999-12-09 Shanghai Second Medical University A human leucine zipper protein gene (bmh) (cblayd06)
BR9915771A (pt) 1998-11-30 2001-12-26 Cytos Biotechnology Ag Apresentação molecular ordenada de antìgenos,processo de preparação e utilização
EP1179013A1 (de) * 1999-05-14 2002-02-13 Medical Research Council Proteingerüst und seine verwendung zur multimerisierung von monomeren peptiden
CA2377731A1 (en) 1999-07-02 2001-01-11 Genentech, Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US20020015951A1 (en) 2000-01-06 2002-02-07 Bader Joel S. Method of analyzing a nucleic acid

Also Published As

Publication number Publication date
DK1362109T3 (da) 2009-07-27
ATE433491T1 (de) 2009-06-15
CA2435000A1 (en) 2002-09-26
EP1362109B1 (de) 2009-06-10
ES2327719T3 (es) 2009-11-03
AU2002252978A1 (en) 2002-10-03
EP1362109A2 (de) 2003-11-19
US7449188B2 (en) 2008-11-11
WO2002074795A3 (en) 2003-09-04
CA2435000C (en) 2014-03-25
AU2002252978B9 (en) 2007-02-01
AU2002252978B2 (en) 2006-12-07
US20040116664A1 (en) 2004-06-17
WO2002074795A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
NO20000850L (no) Vaksine
ATE475675T1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
ATE374042T1 (de) Fc-fusionsproteine zur erhöhung der immunogenität von protein- und peptid-antigenen
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
CY1117551T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ATE496063T1 (de) Hybrid und tandemproteine von neisseria sp
DE60132893D1 (de) Antigene polypeptide
NO20033673D0 (no) Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur
ATE245164T1 (de) Rekombinanter papillomavirus l1
UY28641A1 (es) Anticuerpos
NO971875D0 (no) Cathepsin 02 protease
ATE520713T1 (de) Identifizierung und veränderung von immundominanten polypeptidepitopen
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
ATE399180T1 (de) Rekombinante polypeptide
DE60228603D1 (de) Antigene und vektoren für impfung
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
ATE469655T1 (de) Bakteriophagenvermittelte impfung
ATE323763T1 (de) Dna & protein bindende miniatur proteine
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
RU2006142760A (ru) Генная вакцина рекомбинантного хемотаксического антигена
DE69301733D1 (de) Impfstoffe gegen Metazoen-Parasiten
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek

Legal Events

Date Code Title Description
8364 No opposition during term of opposition